The PennZone

  • Home
  • Business
  • Construction
  • Health
  • Entertainment
  • Travel
  • Music
  • Real Estate
  • Technology

Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023
The PennZone/10233330

Trending...
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
  • Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
  • Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
PHILADELPHIA, June 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several investor conferences in June 2023. These investor conferences include:

Jefferies Global Healthcare Conference
  • Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.
  • Friday, June 9 at 10:00 am EDT.
  • New York City

Baird's Biotech Discovery Series
  • Steven Kelly, President and Chief Executive Officer, and Michael Klichinsky, PhD, Co-Founder and Chief Scientific Officer, will participate in a fireside chat.
  • Wednesday, June 21 at 1:30 pm EDT.
  • Virtual

Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts will be archived at the Company's past events section of the Investor Relations webpage for a limited time following the event.

About Carisma
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

More on The PennZone
  • Greg Wier Announces the Release of More Than Just Luck
  • Coin Claims Services Expands Into Philadelphia and Pittsburgh
  • Nieuwe standaard in webdesign: Professionele website laten maken voor het MKB vanaf €249 door Websitepioniers
  • Shipping Containers Are Powering the Next Generation of Bitcoin Mining Infrastructure
  • Hypnotherapy Finder Announces Official US Wide Launch After Successful Soft Launch

Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Carisma's business, strategy, future operations, cash runway, the advancement of Carisma's product candidates and product pipeline, and clinical development of Carisma's product candidates, including expectations regarding timing of initiation and results of clinical trials, and participation by Carisma in future healthcare industry and investor conferences. The words ""anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "outlook," "plan," "project," "potential," "predict," "target," "possible," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause Carisma's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" set forth in Exhibit 99.3 to Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Carisma's most recent filings with the Securities and Exchange Commission. Any forward-looking statements that are made in this press release speak as of the date of this press release. Carisma undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

More on The PennZone
  • Melzi Job Coach Launches on iOS and Android: A Privacy-First AI Career Engine Built for Execution
  • Technology Leader and Army Veteran Releases Memoir on Late Autism Diagnosis
  • Training Lofts Launches $1,099 Unlimited Training Membership Featuring Semi-Private Coaching, Nutrition Support, and Recovery Services
  • God's Meal Barrel Announces Participation in Give Local York
  • American Properties Realty, Inc. Leadership Attends NAHB International Builders' Show in Florida

Media Contact:
Julia Stern
(763) 350-5223
[email protected]

Investor Contact:
[email protected]

SOURCE Carisma Therapeutics Inc.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • JKS Financial Marks Five-Year Partnership with University of Pittsburgh Basketball, United Way
  • Energywise Solutions and Pickleball Pros Partner to Bring More Energy and Visibility to Pickleball Clubs
  • Buildout Launches CRM, Completing the Industry's First AI-Powered End-to-End Deal Engine for CRE
  • The Franchise King® Releases Free Guide for Nervous Buyers
  • Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
  • CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
  • NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
  • Revenue Optics Launches Talent Infrastructure Platform for SaaS Revenue Hiring and Appoints Sabz Kaur to Lead Growth
  • Building a Multi-Domain Autonomous Systems Platform at the Intersection of AI, Defense and Infrastructure: VisionWave Holdings (N A S D A Q: VWAV)
  • Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
  • Author Ken Mora to Celebrate New Caravaggio Book Debut with Special Event at Palazzo Venezia Naples
  • Matthew Sisneros Releases Raw and Unfiltered Memoir: The Devil Lost Another One — A Powerful Story of Crime, Consequence, and Redemption
  • From Life to Light: Jess L. Martinez Shares a Soulful Poetry Collection That Explores What It Means to Be Human
  • Lawsuit Filed Against Boeing Over Defective Seat Switch on Boeing 787
  • Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
  • Danholm Collection Announces Sale of 16689 Broadwater Ave in Winter Garden, Highlighting Strong Performance in Twinwaters Community
  • South Philadelphia Filmmakers Launch Fourth Feature Film on Amazon Prime Video
  • Strong Clinical Results for Breakthrough Liver Diagnostic Platform; ENDRA Life Sciences (N A S D A Q: NDRA) $NDRA
  • 46th International Symposium On Forecasting – Dates, Venue And Speakers Announced
  • Phoenix Rebellion Therapy Celebrates 10 Years Helping Utahns Overcome Trauma as Utah Faces Nation's 2nd-Highest Rate of Mental Health Challenges

Popular on PennZone

  • Cold. Clean. Anywhere. Meet FrostSkin
  • Ice Melts. Infrastructure Fails. What Happens to Clean Water?
  • The Legal AI Showdown: Westlaw, Lexis, ChatGPT… or EvenSteven?
  • Kilmaine Saints to Anchor St. Patrick's Day Weekend with Live Album Recording at XL Live
  • When Representation No Longer Reflects the District — Why I'm Voting for Pete Verbica
  • Apostle Margelee Hylton Announces the Release of Third Day Prayer
  • Diversified Roofing Solutions Strengthens Industry Leadership With Expanded Roofing Services Across South Florida
  • Revolutionary Data Solution Transforms Health Insurance Underwriting Accuracy
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week

Similar on PennZone

  • Airport Transportation Reaches All Five Continents Through Global Transportation Partner Network
  • Acquisition of Israeli Defense Manufacturing Platform to Accelerate AI-Driven Autonomous Systems: VisionWave Holdings, Inc.: (N A S D A Q: VWAV)
  • HRC Fertility to Celebrate Grand Opening of New Beverly Hills Location During National Infertility Awareness Week
  • Greg Wier Announces the Release of More Than Just Luck
  • Nieuwe standaard in webdesign: Professionele website laten maken voor het MKB vanaf €249 door Websitepioniers
  • $317M Revenue and a Clear Path to $1B: $IQST is Positioned for a Major Profitability Inflection
  • Scotch Whisky Market Dislocation Creates Compelling Entry Opportunity for Long-Term Investors
  • $6 Million Funding Secured as Retail Expansion, Operational Streamlining, and Asset-Light Strategy Position the Company for Accelerated Growth $SOWG
  • The "Unsexy" Business Quietly Creating 130+ New Entrepreneurs Across America — From Alaska to Puerto Rico
  • Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us